相关实验视频

Updated: Sep 18, 2025

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

一个类似于提奥普林的突变性过程定义了TGCT亚型

Kevin M Brown¹, Jun Zhong¹, Adriana Morales Miranda¹

¹Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.

bioRxiv : the preprint server for biology

|June 26, 2025

概括

丸生殖细胞瘤 (TGCTs) 显示出独特的基因组特征,包括X染色体变异和早期全基因组翻倍. 一种新型突变特征,SBS87,在非精子瘤中普遍存在,表明对TGCT发育的潜在环境影响.

科学领域:

基因组学就是基因组学.
在瘤学瘤学.
发育生物学发展生物学

背景情况:

丸生殖细胞瘤 (TGCTs) 是年轻人中最常见的男性癌症.
了解TGCT亚型之间的分子差异对于向治疗至关重要.
TGCTs具有独特的发育起源和高化学敏感性.

研究的目的:

对未经治疗的初级TGCT进行全面的基因组分析.
为了确定新的驱动基因,并定义TGCT亚型的分子特征.
调查全基因组倍增 (WGD) 和特异突变特征在TGCT病变发生中的作用.

主要方法:

252个初级TGCT的深度全基因组测序.
整合匹配的转录和表观基因组数据.
在TGCT亚型之间对基因组特征的比较分析 (种子瘤与非种子瘤).

主要成果:

识别新的驱动基因和广泛的X染色体放大与亚型特定的无活化.
与发病时的年龄相关的无处不在,早期的全基因组翻倍 (WGD) 的特征.
发现一种新型突变特征 (SBS87),在TGCT中普遍存在,特别是非精子瘤中,与延长瘤潜伏时间和端粒延长有关.

结论:

TGCTs在分子上是不同的,是由早期的基因组不稳定性形成的.
亚型特定的基因组特征,包括X染色体变异和WGD模式,可以区分精子瘤和非精子瘤.
在TGCT中发现的新型SBS87突变特征表明潜在的环境或内源病因模仿DNA损伤.

更多相关视频

A Novel Saturation Mutagenesis Approach: Single Step Characterization of Regulatory Protein Binding Sites in RNA Using Phosphorothioates

A Novel Saturation Mutagenesis Approach: Single Step Characterization of Regulatory Protein Binding Sites in RNA Using Phosphorothioates

Published on: August 21, 2018

The Lambda Select cII Mutation Detection System

The Lambda Select cII Mutation Detection System

Published on: April 26, 2018

相关概念视频

Spontaneous and Induced Mutations

Spontaneous and Induced Mutations

Spontaneous mutations arise infrequently during DNA replication due to errors in the process. A key factor behind these errors is tautomeric shifts in nitrogenous bases, where bases transition from keto to enol forms or amino to imino forms. This shift can alter base-pairing rules, leading to mutations. Additionally, reactive oxygen species (ROS) arising from aerobic metabolism can damage DNA, resulting in depurination (loss of a purine base) or depyrimidination (loss of a pyrimidine base).

Mutagenicity and Carcinogenicity

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...

Mutations

Mutations

Cancer-Critical Genes II: Tumor Suppressor Genes

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

Mismatch Repair

Mismatch Repair

TGF - β Signaling Pathway

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...